Tuesday, December 6, 2011

Obama fights for Jewish support amid GOP attacks (AP)

WASHINGTON ? President Barack Obama and his Republican opponents are clashing over U.S. policy toward Israel as each side jockeys for support from Jewish voters, who could be critical in the 2012 election.

Aiming to cast Obama as unfairly harsh toward Israel and soft on the Palestinians, Republican presidential hopefuls Mitt Romney and Newt Gingrich have called on the president to fire his ambassador to Belgium. The envoy, Howard Gutman, had said that some anti-Semitism stemmed from tensions between Israel and the Palestinians; Romney and Gingrich say his remarks unfairly blamed Israel.

The White House says Obama has a strong record on support for Israel, and quickly fired back with a statement condemning "anti-Semitism in all its forms." The State Department said Gutman would remain in his job.

Republicans also challenged Obama's assertion at a fundraiser last week that "this administration has done more in terms of the security of the state of Israel than any previous administration." Romney said Obama has "repeatedly thrown Israel under the bus" ? an accusation the Republican National Committee repeated Monday.

Firing back, Democratic National Committee Chairwoman Debbie Wasserman Schultz called Romney's comments "outrageous" and questioned his own policies. The White House cited military aid to Israel and support at the United Nations, and pointed to statements from Israeli officials backing up Obama's assertion.

The fiery debate will likely continue Wednesday when the GOP presidential candidates attend a Washington forum hosted by the Republican Jewish Coalition.

Obama campaign officials say they will be ready to respond. And the next day, Jewish leaders will be at the White House for briefings on Israel and a Hanukkah party, followed by an Obama speech next week to an expected audience of nearly 6,000 at a conference of the Union for Reform Judaism.

Such attention is all being paid in recognition that Jewish voters, though comprising only 2 percent of the electorate nationwide, are an important part of Obama's base and could make the difference in battleground states including Florida, Pennsylvania, Ohio and Nevada in a close election. Moreover, the Jewish community is an important source of donations, and Obama campaign supporters want to maintain that support as much as Republicans want to chip away at it.

"This campaign takes the Jewish vote very, very seriously," said Ira Forman, the Obama campaign Jewish outreach director. "I'm confident this will be the most comprehensive effort in presidential campaign history."

The White House outreach has increased since May when Obama caused a furor by calling for Israel's 1967 borders, with agreed-upon land swaps, as a basis for resuming negotiations toward a two-state solution with the Palestinians. Israeli Prime Minister Benjamin Netanyahu rejected the `67 borders as indefensible and largely disregarded Obama's emphasis on land swaps to account for current conditions.

Republicans seized on the dispute. And while Obama supporters say his argument was widely mischaracterized, damage was done. Now the Obama campaign and its backers say they are determined to respond rapidly to such criticism in future.

"We are trying to responsibly respond to all of these unsubstantiated or false allegations, but there are so many of them, and they are so frequently recited despite the fact that the people who are spreading them have to know that they're false, that it's hard to keep up with them," said Alan Solow, an Obama fundraiser and longtime associate.

The effort involves using surrogates including Vice President Joe Biden, and use of the president's own time in public appearances and private talks with donors and religious leaders, such as a conference call between Obama and rabbis ahead of the Jewish New Year this fall.

The Obama campaign also is going on the offense against Republicans. In conversations about the Jewish vote, Obama backers are quick to bring up comments by Romney, Gingrich and Rick Perry at a debate last month suggesting they would start foreign aid for all countries at zero. Obama supporters say would imperil funding for Israel, even though the candidates also sought to affirm their support for the Jewish state.

Democratic candidates typically enjoy a big electoral advantage among Jewish voters. Obama won 78 percent of the Jewish vote in 2008, compared with 21 percent for Republican John McCain.

But Gallup has found that Obama's approval rating among Jews has fallen from 83 percent in January 2009 to 54 percent in late summer and early fall of this year. Still, that figure is much higher than his overall 41 percent approval rating, and the drop-off in support was about in line with other voter groups.

Sid Dinerstein, chairman of the Palm Beach County Republican Party in Florida, predicted that Obama would be limited to around 60 percent of the Jewish vote in 2012. Obama backers say that won't happen, but it could mean a potentially decisive difference of tens of thousands of votes in key states.

A candidate's position on Israel may not be the top issue for most Jewish voters, who like others are more motivated by jobs and the economy. But it's important to many, and Republicans see an opening, given the consternation over Obama's 1967 borders speech, his administration's rebukes of Israel for building settlements in disputed areas, and a recent incident in which Obama was overheard appearing to endorse criticism of Netanyahu from French President Nicolas Sarkozy.

"The reality is that the Jewish community understands that on a number of critical issues this administration has undermined not only the U.S.-Israel relationship, but has made Israel more vulnerable," said Matt Brooks, executive director of the Republican Jewish Coalition.

Brooks points to the recent upset in New York's special election to replace Democratic Rep. Anthony Weiner, in which Republican Bob Turner won in the heavily Jewish district. Brooks says this was a warning sign to Obama on his stance on Israel. Obama supporters say other factors were at play, including the heavily Orthodox and more conservative makeup of the district.

But even strong supporters are disappointed that Obama has not yet traveled to Israel in his capacity as president, after delivering a major speech in Cairo early in his administration. An Israel trip had been rumored to be in the works but seems unlikely to happen prior to the 2012 election.

Democratic Rep. Steve Rothman said he remains hopeful a trip will happen in the next year.

"No president has been perfect on every subject, though history will record that Obama has been the best president for Israel when it comes to military and intelligence support," said Rothman of New Jersey.

Source: http://us.rd.yahoo.com/dailynews/rss/religion/*http%3A//news.yahoo.com/s/ap/20111205/ap_on_el_ge/us_obama_jewish_voters

portland news portland news tibetan mastiff manny pacquiao pacquiao blanche blanche

Sunday, December 4, 2011

Hitting The 'Off' Switch On Antibiotic Resistance

Doctors are running out of effective antibiotics, as bacteria evolve ways to evade one drug after another. Now DARPA has called for alternatives to conventional antibiotics. Nanotechnologist Chad Mirkin discusses one such weapon?tiny globs of DNA and RNA that can switch off the bugs' antibiotic resistance. Nanotechnologist Chad Mirkin discusses next-generation antibiotics that target a bacterium's DNA.

Copyright ? 2011 National Public Radio?. For personal, noncommercial use only. See Terms of Use. For other uses, prior permission required.

IRA FLATOW, HOST:

This is SCIENCE FRIDAY. I'm Ira Flatow. In the battle of antibiotics versus bacteria, the bugs are winning. Not only are they evolving resistance to our arsenal of drugs, but we're running out of new antibiotics to launch at them. And antibiotic-resistant bacteria aren't just a problem for hospitals and patients. Think about wounded soldiers on the battlefield, infected with superbugs or a bioterrorism attack using resistant or engineered pathogens.

Would we be able to handle it? That's why DARPA, the research arm of the Defense Department, has called on scientists to develop new, next-generation antibiotics. One promising technology is DNA-based drugs that not only target the superbugs, but they can evolve right along with them, preventing antibiotic resistance.

Chad Mirkin is director of the International Institute for Nanotechnology at Northwestern University in Evanston, Illinois. Welcome back to SCIENCE FRIDAY, Dr. Mirkin.

DR. CHAD MIRKIN: It's a pleasure to be here.

FLATOW: These are little nanoparticle-sort-of-sized things?

MIRKIN: Yeah, they're really interesting structures. In fact, their structure is made out of DNA or RNA that are made on a gold nanoparticle, in fact a variety of different types of particles, but they're strands of DNA that are arranged on the surface of these spherical particles.

And when you make them in this manner, they have properties that are very different from the normal type of DNA that we're all familiar with, duplex, linear type of DNA, and one of those properties is they have the ability to enter cells, including bacterial cells, very, very efficiently.

FLATOW: And when they get in the cell, what do they do?

MIRKIN: Well, the beauty is what we can do. We can design them so that they can go in and flip switches, genetic switches, that either turn off resistance so that a conventional antibiotic will work or, better yet, stop replication and ultimately cause bacterial cell death.

FLATOW: So is there then no need for a standard antibiotic?

MIRKIN: Well, this would be a different route to the standard antibiotics, which are typically small molecules. This would be a genetic-based root, and the beauty of that is that, as you said in your opening, you can move with the bug. As the bug evolves, you can change the sequence and target different genetic components of the bug so that you can constantly battle its response to the new drug.

FLATOW: So as the bug changes, you tailor-make the new stuff to mimic what the bug is doing.

MIRKIN: That's the idea. I mean, this is very early in this whole process. This is actually part of a big platform that we call spherical nucleic acids that we've been developing at Northwestern now for about 15 years and are part of a company that we started called Arosense(ph) that can really go after any sort of genetic disease.

And that's the beauty of it: You can tailor it on a disease-by-disease basis, as long as you have good genetic information about the different types of switches that you have to turn on or off to effect treatment.

FLATOW: If you have - then if you have genetic diseases that are not, you know, antibiotic related, maybe like cancer or something like that, could you not go in and stop the cancers from spreading that way?

MIRKIN: That's exactly right. In fact, we have a very active program in that regard. The beauty of these constructs, they're part of a larger field called gene regulation, which actually has won the Nobel Prize for its promise, the idea that you could use this - a concept of switching off genes or down-regulating genes so that you could adjust protein levels and take effectively a diseased cell and make it healthy, or in the case of a cancer selectively cause it to die.

The problem with conventional approaches is that they often have to have materials to help carry the genetic material into the cells, and they're not very good at targeting. In addition, they cause all sorts of toxic side effects. So you run into the problem where the therapy causes as many problems as the disease originally did.

In this case, these structures, this kind of spherical form of nucleic acid, has this incredible property that it requires no co-carrier. You can treat diseases based upon that genetic information, and you can either locally deliver - for example we have projects with a dermatologist named Amy Paller, where we have the first constructs that can be delivered through the skin to go after things like melanoma and psoriasis.

Or another project involves a guy named Alex Steig(ph), where we're going after brain cancer, and we can systemically deliver these. They go everywhere, but they cause no toxic side effects, and so they accumulate in a lot of cells, including tumor cells in the brain, and you can selectively go after those cells based upon the genetic differences of those cells causing them to selectively die.

FLATOW: So even though they get into the cells, their little genetic pieces don't match up with the wrong cells then?

MIRKIN: That's exactly right. You've got almost a lock-and-key type of shutoff here.

FLATOW: You know, there are a lot of people who were concerned about pumping a bunch of nanoparticles into their body, and I guess they would be concerned about this, too.

MIRKIN: Well, potentially. I mean, the interesting thing about this is, so typically, we will use a gold particle, and we'll arrange the nucleic acid, the DNA or RNA on the surface on the particle. And that itself can be a therapeutic, and we have a lot of therapeutic leads based upon those types of materials.

But we've also figured out ways of what's called cross-linking, attaching the DNA strands on the surface of the particle to each other, and we can dissolve the gold, and we literally can use effectively pure nucleic acid in that case. And those types of constructs work just as well.

FLATOW: All right, now for the $64 question, which I know you knew would be coming, right? You could probably ask it of yourself: When are we going to have a product that is going to be available to try?

MIRKIN: Well, I think the more important question to ask is when are we going to go into trials. So we have incredible in-vivo data in animals, small animals, that suggests that this works and works extremely well. And it can do things that frankly no other gene regulation construct has ever done before, and that is delivery through the skin, very effectively, knock down in animals and also this idea of systemic delivery.

And what's really difficult in this field is getting these big drugs - because they're big particles compared to the small-molecule drugs that we've been talking about - getting them across the blood-brain barrier. And the beautiful thing about these constructs is they show the ability to do that.

And so the real question is how soon will we be into trials? And we're really shooting for next year. So we're hopeful that we're going to be into human trials sometime next year, pushing for the early part but certainly before the end of the year.

FLATOW: And as far as antibiotics are considered, do you consider them old hat now?

MIRKIN: No, I wouldn't consider them old hat. I mean, this may end up being a co-therapy, or it may be a replacement for existing antibiotics. But a lot of work has to be done. So the DARPA program is actually new. It was I think really insightful for them to take this on and to challenge the community to come up with new ways because the world desperately needs these types of constructs.

We have to really go through and validate these in the context of bacteria, like we have in the context of diseases like cancer in small animals. And so what we're going to be doing over the next year on the bacteria side of things is really starting with cells and then moving up through bacteria and then animal studies.

FLATOW: And why is it that DARPA has to jump in here? What's wrong with our own medical system?

MIRKIN: Well, DARPA - I don't know if it's a matter of what's wrong. It's a matter of creating challenges. And so there are business challenges, and one of the problems, of course, in the antibiotic area is that from a drug standpoint, they're not nearly as big a market as, for example, an oncology type of drug.

But there are also just challenges in - grand challenges in terms of chemistry and material science that have to be overcome, and you have to get a lot of different folks together to solve big problems. And DARPA is extremely good at doing that.

They move very rapidly when they recognize you have a big problem. They're able to first of all put together substantial resources, which is needed in this case, to challenge the academic community in this case to come up with alternative solutions and to think outside of the box. And they're one of the best agencies for doing that.

FLATOW: So what you're saying is that the people are willing to spend money on the military to do this where they might not in the civilian case.

MIRKIN: Well, yeah, the military has a different set of drivers, right. So they're not...

FLATOW: So where we used to think of the military as making weapons and transistors and things, they're now making drugs.

MIRKIN: They make a lot of things. They made our GPS, as well. They make a lot of things that positively affect civilians in day-to-day life, and this would be a big one.

FLATOW: All right, thank you very much, Dr. Mirkin, for taking time to be with us. We'll have you back on when you get some results, when the trials begin.

MIRKIN: Thank you.

FLATOW: Chad Mirkin is director of the International Institute for Nanotechnology at Northwestern University in Evanston, Illinois.

Copyright ? 2011 National Public Radio?. All rights reserved. No quotes from the materials contained herein may be used in any media without attribution to National Public Radio. This transcript is provided for personal, noncommercial use only, pursuant to our Terms of Use. Any other use requires NPR's prior permission. Visit our permissions page for further information.

NPR transcripts are created on a rush deadline by a contractor for NPR, and accuracy and availability may vary. This text may not be in its final form and may be updated or revised in the future. Please be aware that the authoritative record of NPR's programming is the audio.

Source: http://www.npr.org/2011/12/02/143055120/hitting-the-off-switch-on-antibiotic-resistance?ft=1&f=1007

much ado about nothing sean hayes caroline manzo caroline manzo the haunting in connecticut ashram ashram

Saturday, December 3, 2011

Penn State pledges $1.5M for sex-crimes groups

FILE - This Nov. 5, 2011 file photo provided by the Pennsylvania Office of Attorney General shows former Penn State football defensive coordinator Gerald "Jerry" Sandusky, who sexually abused a boy more than 100 times, then threatened his family to keep him quiet about the encounters, according to a lawsuit filed Wednesday, Nov. 30, 2011 that details new accusations not included in criminal charges against him. (AP Photo/Pennsylvania Office of Attorney General, File)

FILE - This Nov. 5, 2011 file photo provided by the Pennsylvania Office of Attorney General shows former Penn State football defensive coordinator Gerald "Jerry" Sandusky, who sexually abused a boy more than 100 times, then threatened his family to keep him quiet about the encounters, according to a lawsuit filed Wednesday, Nov. 30, 2011 that details new accusations not included in criminal charges against him. (AP Photo/Pennsylvania Office of Attorney General, File)

Penn State President Rodney Erickson, left, responds to a question as Acting Executive Vice President and Provost Rob Pangborn, center, and Vice President for Student Affairs Damon Simons look on during a town hall forum organized by students at the university's main campus, Wednesday, Nov. 30, 2011, in State College, Pa. The event served as an open discussion between students and the administration about the school's recent sexual abuse scandal, which has resulted in the departures of school President Graham Spanier and longtime football coach Joe Paterno. (AP Photo/John Beale)

Penn State President Rodney Erickson speaks at a town hall forum organized by students at the university's main campus, Wednesday, Nov. 30, 2011, in State College, Pa. The event served as an open discussion between students and the administration about the school's recent sexual abuse scandal, which has resulted in the departures of school President Graham Spanier and longtime football coach Joe Paterno. (AP Photo/John Beale)

Penn State President Rodney Erickson, left, responds to a question as Acting Executive Vice President and Provost Rob Pangborn, center, and Vice President for Student Affairs Damon Simons look on during a town hall forum organized by students at the university's main campus, Wednesday, Nov. 30, 2011, in State College, Pa. The event served as an open discussion between students and the administration about the school's recent sexual abuse scandal, which has resulted in the departures of school President Graham Spanier and longtime football coach Joe Paterno. (AP Photo/John Beale)

Penn State President Rodney Erickson, right, gives his opening remarks as T.J. Bard, president of the University Park Undergraduate Association, and Peter Khoury, president of The Council of Commonwealth Student Governments, look on during a town hall forum organized by students at the university's main campus, Wednesday, Nov. 30, 2011, in State College, Pa. The event served as an open discussion between students and the administration about the school's recent sexual abuse scandal, which has resulted in the departures of school President Graham Spanier and longtime football coach Joe Paterno. (AP Photo/John Beale)

(AP) ? Penn State will donate $1.5 million in bowl proceeds to a pair of groups that work with sex-crime victims, a gesture aimed at healing the school's battered image in the wake of child sex charges against a former assistant football coach.

University President Rod Erickson promised the donation the morning after he and other administrators faced pointed questions at a student-organized town hall forum.

Erickson told The Associated Press in an interview Thursday that the Big Ten bowl revenue, which usually goes back to the athletic department, will go instead to the Pennsylvania Coalition Against Rape and the National Sexual Violence Resource Center.

"This presents an excellent opportunity for Penn State to raise the national visibility of this issue," Erickson said. "Our students and fans are focused on a cause to play for, to cheer for."

Also Thursday, Jerry Sandusky's lawyer said he has not discussed pleading guilty with his client and that the former coach continues to maintain he is innocent of the charges against him.

Joe Amendola said he would consider "possible alternatives" with Sandusky if new charges are filed that involve more victims than the eight boys covered by the 40 pending criminal counts, but that Sandusky has never considered a plea in his case. Sandusky, 67, is awaiting a preliminary hearing.

Amendola said the topic of a guilty plea came up as a "what if" question from a reporter about potential additional charges.

"My answer to the 'what if' question was analogous to saying, if weather forecasters were predicting a blizzard next week, which they are not, I would have to at least consider the possibility of postponing my scheduled trip to Philadelphia," Amendola said in an email.

In another development, lawyers for a young man described in a grand jury report as a victim of sexual abuse by Sandusky said Thursday they had settled a legal action regarding a charity's assets.

Harrisburg attorneys Ben Andreozzi and Jeffrey Fritz said the settlement protected the claim their client plans to assert to the assets of The Second Mile, a nonprofit for at-risk children Sandusky founded in 1977.

"We intend to initiate a civil lawsuit seeking damages from the organizations and individuals responsible for the sexual assaults upon our clients," the lawyers said in a release. "However, our priority at this time is to support our clients, including Victim No. 4, who will be testifying against Mr. Sandusky at the preliminary hearing."

Andreozzi and Fritz said that under terms of the settlement, The Second Mile has agreed to obtain court approval before transferring assets or closing and give their client the ability to weigh in before a judge regarding any distribution of assets.

The Second Mile released a statement calling the agreement a reiteration of its existing legal liabilities and saying it does not include a finding of liability.

The Second Mile said earlier this week that its donors should consider giving their money instead to the Pennsylvania Coalition Against Rape, the latest sign that the charity may not be around much longer. The Second Mile said its December programs would go on as scheduled, however.

The Wednesday night forum on Penn State's main campus came on the heels of fresh sex abuse allegations against Sandusky, who was accused in a lawsuit of sexually abusing a young boy more than 100 times after meeting him through his charity.

The state police commissioner has criticized school leaders for failing to do more to alert authorities to the allegations, and Erickson told about 450 attendees at a crowded auditorium at the student union building that ethics would be raised "to a new level so that everyone at the university understands not just the legal thing to do, but the moral thing to do, so that we learn to do the right thing the first time, every time."

Students appeared grateful to get answers more than three weeks after Sandusky was charged Nov. 5, hopeful it would aid in the arduous healing process.

"I think this is a good start for a lot of good things that can happen at the university," said student Andrew Comes, 21, following the two-hour forum. "It's a singularly bad event, but there can still be positive repercussions and good things happening from it."

Administrators sought to reassure students worried about the unintended ramifications of the scandal, such as the reputation of a Penn State degree.

After several questioners mentioned they felt shamed by the scandal, vice president Henry Foley, as part of an answer about the school's top three priorities, told students to focus on academics and to "recognize that none of you are guilty. ... You may feel shame, but none of you are guilty. Just keep doing what you came here to do."

The scandal has resulted in the departures of head coach Joe Paterno and university President Graham Spanier. Athletic Director Tim Curley has been placed on administrative leave, and Vice President Gary Schultz, who was in charge of the university's police department, has stepped down.

Schultz and Curley are charged with lying to the grand jury and failure to report to police. They also maintain their innocence and have a preliminary hearing later this month.

Erickson told reporters after the forum that Spanier was on sabbatical and that as a tenured faculty member would have the right to teach if he so desired.

Several students also asked about the treatment of Paterno, who was the only school leader fired in the scandal's aftermath. Erickson said afterward he could not offer a detailed answer because it was the trustees' decision.

He reiterated there was no truth to Internet-fueled rumors that Paterno's statue outside Beaver Stadium would be removed or that the Paterno name would be removed from the campus library for which the Paterno family has donated millions of dollars.

"At some appropriate time down the road, I'm sure there will be an opportunity to also reflect on the many years of service Joe and (wife Sue Paterno) provided the university and the many good things that they've done for Penn State," Erickson said, eliciting brief applause.

Associated Press

Source: http://hosted2.ap.org/APDEFAULT/347875155d53465d95cec892aeb06419/Article_2011-12-01-Penn%20State-Abuse/id-cb445ffd04b74a13acf3e3718fd2731c

the waltons the waltons weta weta sugar cookie recipe sugar cookie recipe toys r us

Friday, December 2, 2011

Billy Graham hospitalized with possible pneumonia (Reuters)

(Reuters) ? Billy Graham, one of America's best-known evangelists, is in a North Carolina hospital with possible pneumonia, and is listed in stable condition, officials with the facility said on Wednesday.

Mission Hospital said in a statement that the 93-year-old Graham was smiling and alert as he waved to staff when he was admitted to the facility in Asheville, North Carolina, for evaluation and treatment of his lungs.

Doctors treating Graham said he possibly has pneumonia but that his condition is stable.

Graham has preached the Christian gospel to millions worldwide and given spiritual advice to numerous U.S. presidents.

"While no date has been set for discharge, Mr. Graham is looking forward to returning home to spend the upcoming Christmas holidays with his family," the hospital statement said.

Graham was treated for pneumonia in May at Mission Hospital. The facility is near his home in Montreat, North Carolina.

His wife, Ruth, died in June 2007.

(Reporting by Alex Dobuzinskis: Editing by Peter Cooney and Jerry Norton)

Source: http://us.rd.yahoo.com/dailynews/rss/us/*http%3A//news.yahoo.com/s/nm/20111130/us_nm/us_billygraham

zack greinke siri san diego news ford evos ford evos ides of march starship troopers

Obama gets an assist from Bill Clinton in latest jobs push (Los Angeles Times)

Share With Friends: Share on FacebookTweet ThisPost to Google-BuzzSend on GmailPost to Linked-InSubscribe to This Feed | Rss To Twitter | Politics - Top Stories Stories, News Feeds and News via Feedzilla.

Source: http://news.feedzilla.com/en_us/stories/politics/top-stories/169120227?client_source=feed&format=rss

x factor judges raiders news raiders news ice cream sandwich android ice cream sandwich android harry belafonte harry belafonte